Induction of nuclear translocation of mutant cytoplasmic p53 by geranylgeranoic acid in a

human hepatoma cell line

Chieko Iwao and Yoshihiro Shidoji*

Molecular and Cellular Biology, Graduate School of Human Health Science, University of Nagasaki,

Academy Hills 1-1-1, Nagayo, Nagasaki 851-2195, Japan

*Corresponding author:

Y. Shidoji, telephone/fax: +81-95-813-5207, e-mail: shidoji@sun.ac.jp

Running title: GGA-induced nuclear translocation of mutant p53

Support: This work was supported in part by a grant-in-aid from the Japan Society for the Promotion of Science (grant number 19590230) and a research-grant B from the University of Nagasaki.



Supplementary Figure S1. GGA effects on nuclear/cytoplasmic distribution of p53 in HuH-7 cells.

Whole-cell lysates of HuH-7 cells were separated into nuclear and cytoplasmic fractions. Protein concentration was determined using Bio-Rad Protein Assay reagent. (a) Fraction samples (5 μ g) were subjected to immunoblotting with anti-p53 antibody. Histone H3 and GAPDH were used as nuclear and cytoplasmic markers, respectively. (b) Coomassie Brilliant Blue stain.



Supplementary Figure S2. Subcellular distribution of p53 in HUH-7 cells.

Whole-cell lysates of HuH-7 cells were separated into nuclear, mitochondrial, post-mitochondrial, cytosolic, and 348900 g supernatant fractions. Protein concentration was determined using the Bio-Rad Protein Assay reagent. Fraction samples (5 µg) were subjected to immunoblotting with an anti-p53 antibody.



Supplementary Figure S3. Uncropped blots probed with anti-p53 (a) and reprobed with anti- β -III-tubulin (b).

Panels **c** and **d** of Figure 4 in the main text were cropped by each 4merging blue-lined squares in panels **a** and **b**, respectively. Unmarked lanes show the samples treated with other ditrepenoids than GGA, which are irrelevant to the present study, so that they were removed.



Supplementary Figure S4. GGA upregulates the *PUMA* gene expression selectively in HuH-7 cells.

(a) HuH-7cells were treated with 0 — 30 μ M of GGA for 8 h, and total mRNA was extracted to analyze PUMA mRNA expression by quantitative RT-PCR. Each point represents the mean ± SE of four independent experiments. (b) HuH-7 cells were treated with or without 20 μ M of GGA for 2, 4, 6, 8, and 24 h. Whole cell lysates and mitochondrial fractions were prepared and the PUMA level was analysed by western blotting. Total β-actin and porin were used as loading controls. (c) HuH-7 cells (p53 Y220C), PLC/PRF/5 cells (p53 R249S), HepG2 cells (p53 wild type), and Hep3B cells (p53 null) were treated with or without 20 μ M of GGA for 0.5, 1, 2, 4, 8, and 24 h, and total mRNA was extracted to analyse *PUMA* mRNA expression by quantitative RT-PCR. Each point represents the mean ± SE for HuH-7 (*n* = 6), Hep3B (*n* = 3), HepG2 (*n* = 3) and PLC/PRF/5 (*n* = 3).



Supplementary Figure S5. Enhancement of transcriptional activation of the *PUMA* promoter by GGA in HuH-7 cells.

(a) Dual luciferase reporter assay with the p53-responsive consensus sequence in HuH-7 cells after 24-h GGA (0 — 20 μ M) treatment. The luciferase activity was normalized by renilla luciferase. The asterisks (*) indicate statistically significant changes (p < 0.05) as determined by the Student's t-test. (b) Dual luciferase reporter assay with p53-responsive 5'-upstream regulatory region of the *PUMA* gene in HuH-7 cells after GGA (20 μ M) treatment. The luciferase activity was normalized by renilla luciferase. The asterisks (*) indicate statistically significant changes (p < 0.05) as determined by the Student's t-test. Student's t-test.

Supplementary Table S1. The nucleotide sequences of each primers used for real-time RT-PCR

Genes		Sequence (5' -3')
p21	F	CTGGAGACTCTCAGGGTCGAAA
	R	GATTAGGGCTTCCTCTTGGAGA
PUMA	F	CCCAAGACTGTTGGGTCTG
	R	GCCGTAGTAATCCGTGAAGAG
TIGAR	F	AGACAGCGGTATTCCAGG
	R	AGAGTGGCTGGTAAGGAAC
SCO2	F	AGAAGCCAGGAGAGGGACGG
	R	CCAGGCCCAGAGTGAAGGAG
DRAM	F	CGCCTTCATTATCTCCTACG
	R	CGAAACATCCCACCAATCCA
28S ribosomal RNA	F	TTAGTGACGCGCATGAATGG
	R	TGTGGTTTCGCTGGATAGTAGGT

F: forward primer, R: reverse primer

Supplementary Table S2. The conditions of thermal cycler for real-time RT-PCR of each genes

p21	Temperature	Slope
Denature	95°C, 600 s	20°C / s
PCR	95°C, 10 s	20°C / s
(45 cycles)	65°C, 20 s	20°C / s
	72°C, 10 s	20°C / s
Melting	95°C, 0 s	20°C / s
	57°C, 15 s	20°C / s
	98°C, 0 s	0.1°C / s
Cooling	40°C, 30 s	20°C / s

PUMA	Temperature	Slope
Denature	95°C, 600 s	20°C / s
PCR	95°C, 10 s	20°C / s
(40 cycles)	61°C, 20 s	20°C / s
	72°C, 20 s	20°C / s
Melting	95°C, 0 s	20°C / s
	61°C, 15 s	20°C / s
	98°C, 0 s	0.1°C / s
Cooling	40°C, 10 s	20°C / s

TIGAR	Temperature	Slope
Denature	95°C, 600 s	20°C / s
PCR	95°C, 10 s	20°C / s
(45 cycles)	56°C, 20 s	20°C / s
	72°C, 15 s	20°C / s
Melting	95°C, 0 s	20°C / s
	57°C, 15 s	20°C / s
	98°C, 0 s	0.1°C / s
Cooling	40°C, 10 s	20°C / s

SCO2	Temperature	Slope
Denature	95°C, 600 s	20°C / s
PCR	95°C, 10 s	20°C / s
(40 cycles)	56°C, 20 s	20°C / s
	72°C, 20 s	20°C / s
Melting	95°C, 0 s	20°C / s
	57°C, 15 s	20°C / s
	98°C, 0 s	0.1°C / s
Cooling	40°C, 30 s	20°C / s

DRAM	Temperature	Slope
Denature	95°C, 600 s	20°C / s
PCR	95°C, 10 s	20°C / s
(60 cycles)	55°C, 10 s	20°C / s
	72°C, 20 s	20°C / s
Melting	95°C, 0 s	20°C / s
	65°C, 15 s	20°C / s
	95°C, 0 s	0.1°C / s
Cooling	40°C, 30 s	20°C / s

28S rRNA	Temperature	Slope
Denature	95°C, 600 s	20°C / s
PCR	95°C, 15 s	20°C / s
(40 cycles)	60°C, 30 s	20°C / s
Melting	95°C, 0 s	20°C / s
	65°C, 15 s	20°C / s
	95°C, 0 s	0.1°C / s
Cooling	40°C, 30 s	20°C / s